Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | AZD2936 |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | AZD2936 | Phase I | Actionable | In a Phase I trial (ARTEMIDE-01), AZD2936 treatment demonstrated acceptable safety and activity in patients with CD274 (PD-L1)-positive (TPS >/= 1%) advanced non-small cell lung cancer, with an overall response rate of 3.9% (3/76, 3 partial responses), stable disease in 39.5% (30/76), disease control rate (DCR) at 9 weeks of 43.4% (33/76), and a DCR at 27 weeks of 14.5% (11/76), with a duration of response of 2.1-6.4 mo (J Clin Oncol 41, 2023 (suppl 16; abstr 9050); NCT04995523). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01. | Full reference... |